PALI News & Events

Palisade Bio announced the presentation of new translational data for PALI-2108 at the 21st Congress of the European Crohn's and Colitis Organization, ECCO, in Stockholm, Sweden. The poster, titled "Oral Locally Bioactivated PDE4 Inhibitor Prodrug PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Phase 1b Translational Findings," highlights data showing that PALI-2108 produced measurable clinical response within seven days, improved histologic markers of inflammation in colon tissue, and reduced key inflammatory biomarkers. The data also demonstrates localized pharmacologic activity in the colon, including reduced PDE4B expression and modulation of inflammatory signaling pathways, supporting the intended targeted mechanism of the program. Access the poster here.

Palisade Bio announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board, CAB. Palisade plans to submit an Investigational New Drug application for a Phase 2 study of PALI-2108 in UC in the first half of 2026, with parallel development planning underway in FSCD.

Palisade Bio announced the appointment of Laurent Peyrin-Biroulet, MD, PhD and David Rubin, MD, two internationally recognized leaders in inflammatory bowel disease, to its Clinical Advisory Board.